Neil Skolnik, MD January 06, 2023 I’m Dr Neil Skolnik. Today we are going to talk about the 2023 GOLD guide for COPD. The big news here is a more streamlined approach to treatment, combining what used to be categories C and D into one category — E — for exacerbations. There is continued emphasis on getting a...
by University of Technology, Sydney Credit: Pixabay/CC0 Public Domain Research led by the Centenary Institute, the University of Technology Sydney and Ghent University Hospital, Belgium has identified a new therapeutic approach for chronic obstructive pulmonary disease (COPD)—the targeting and inhibition of a protein called RIPK1. The third leading cause of death worldwide and with no...
by University of Toronto Credit: Pixabay/CC0 Public Domain Chronic Obstructive Pulmonary Disease (COPD)—a debilitating chronic lung disease that includes emphysema and chronic bronchitis—has previously been linked to mental health problems, such as depression, anxiety, and substance use disorders. But a new study by University of Toronto researchers found that, even though adults without the disease...
JAMA NETWORK Bottom Line: The U.S. Preventive Services Task Force (USPSTF) recommends against screening for chronic obstructive pulmonary disease (COPD) in asymptomatic adults who do not recognize or report respiratory symptoms. Chronic obstructive pulmonary disease is an irreversible reduction of airflow in the lungs. Progression to severe disease can prevent participation in normal activities because of...
by Bob Yirka, Medical Xpress Overview of the transcriptomics-guided drug discovery strategy.(A) Schematic outline of the drug screening strategy. (B) Heatmap shows the gene expression pattern of the druggable genes (www.dgidb.org) identified both in CS-exposed mice and patient with COPD databases. (C) Reactome pathway enrichment analysis of genes differentially expressed from patients with COPD (8)...
Chronic Obstructive Pulmonary Disease, or COPD, is the third leading cause of death worldwide. Yet despite its prevalence, the disease is not well understood on a cellular level. New Yale research has provided an unprecedented atlas of the cells in the COPD-afflicted lung, identifying those cells and pathways that may contribute to the reduced lung...
JANUARY 14, 2022 by Ludwig Maximilian University of Munich Immunofluorescence image of lung tissue showing co-localization of TRPML3 (green) and macrophages (red). Credit: Barbara Spix Chronic obstructive pulmonary disease—COPD for short—is one of the most common diseases of the lung. It affects almost 300 million people worldwide, of which about three million die every year. A...
JANUARY 11, 2022 by University College London Micrograph showing emphysema (left – large empty spaces) and lung tissue with relative preservation of the alveoli (right). Credit: Wikipedia The global burden of Chronic Obstructive Pulmonary Disease (COPD), a group of common lung conditions that affects more than 300 million people, could be significantly reduced with a simple...
IMAGE: MESENCHYMAL STROMAL CELLS (MSCS) ARE POTENT IMMUNOMODULATORS THAT HAVE SHOWN PROMISE IN TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). USING TRANSCRIPTOMICS, RESEARCHERS HAVE DEMONSTRATED THAT MSC INFUSIONS ELICIT A STRONG, YET TRANSIENT (<7 DAYS) TRANSCRIPTIONAL RESPONSE IN CIRCULATING MONONUCLEAR CELLS OF COPD PATIENTS, ATTENUATING KEY PRO-INFLAMMATORY PATHWAYS. THESE RESPONSES ARE LIKELY MEDIATED BY SOLUBLE FACTORS...
by Mark Derewicz, University of North Carolina at Chapel Hill School of Medicine Micrograph showing emphysema (left – large empty spaces) and lung tissue with relative preservation of the alveoli (right). Credit: Wikipedia Airway mucus consists of various proteins such as long mucins MUC5AC and MUC5B, both of which contribute greatly to the proper gel-like consistency...
